DSpace JSPUI


DSpace preserves and enables easy and open access to all types of digital content including text, images, moving images, mpegs and data sets

Learn More

Please use this identifier to cite or link to this item: http://repositorio.insp.mx:8080/jspui/handle/20.500.12096/7965
Title: Consenso mexicano sobre probióticos en gastroenterología
Keywords: Gastroenterology,Adultos, Adults Children Consenso Consensus Enfermedades gastrointestinales Gastrointestinal diseases Mexico México Niños Probiotics Probióticos.
Issue Date: 2017
Publisher: ESPM INSP
Abstract: Introduction Probiotics are frequently prescribed in clinical practice. Their efficacy in treating gastrointestinal disorders is supported by a significant number of clinical trials. However, the correct prescription of these agents is hampered due to a lack of knowledge of the scientific evidence and to the different presentations and microbial compositions of the probiotics that are currently available. Aim: To provide the clinician with a consensus review of probiotics and recommendations for their use in gastroenterology. Materials and methods: Controlled clinical trials, meta-analyses, and systematic reviews published up to 2015 were selected, using the MESH terms: probiotics, gastrointestinal diseases, humans, adults, AND children. The Delphi method was employed. Eighteen gastroenterologists treating adult patients and 14 pediatric gastroenterologists formulated statements that were voted on until agreement>70% was reached. The level of evidence based on the GRADE system was evaluated for each statement. Results and conclusions: Eleven statements on the general concepts of probiotics and 27 statements on the use of probiotics in gastrointestinal diseases in both adults and children were formulated. The consensus group recommends the use of probiotics under the following clinical conditions: the prevention of diarrhea associated with antibiotics, the treatment of acute infectious diarrhea, the prevention of Clostridium difficile infection and necrotizing enterocolitis, the reduction of adverse events from Helicobacter pylori eradication therapy, relief from irritable bowel syndrome symptoms, the treatment of functional constipation in the adult, and the induction and maintenance of remission in patients with ulcerative colitis and pouchitis, and the treatment of covert and overt hepatic encephalopathy.
URI: sicabi.insp.mx:2017-None
https://reader.elsevier.com/reader/sd/pii/S0375090616300933?token=7C4E3BF0EE2975943BEC237320A7E2BEFE30487354C575253215377DD942C209D65AC46624F7031F88563A2D7737091C
https://www.doi.org/10.1016/j.rgmx.2016.08.004
http://repositorio.insp.mx:8080/jspui/handle/20.500.12096/7965
Appears in Collections:Artículos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.